Yescarta competitor: Kymriah has manufacturing problems | GILD Message Board Posts

Gilead Sciences, Inc.

  GILD website

  • TECH UPDATE: Since we don't serve ads to Premium Members, our "premium" URL is not affected by the new code now required by our ad partners. So, rather than wait for us to resolve all these lovely new code conflicts suddenly plaguing our free, ad-supported "www" pages  (a process which will likely take days), Premium Members can enjoy full site functionality now by simply logging in to their premium accounts at https://premium.investorvillage.com If you need password assistance, don't hesitate to contact us. That's what we're here for.  


GILD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  11835 of 11892  at  12/11/2018 8:16:45 AM  by

captsolo


 In response to msg 11834 by  mymorningsong
view thread

Re: Yescarta competitor: Kymriah has manufacturing problems

"Yet, about eight months on from securing a second approval for Kymriah (tisagenlecleucel), the company is still delivering the CAR-T treatment to some patients for free, unable to charge for a product that while OK for use in patients doesn't meet stricter specifications established for commercial use."


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 212
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...